BioCardia (BCDA) Free Cash Flow Growth (3y) (2015 - 2026)
Analysis
BioCardia (BCDA) Free Cash Flow Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 60.54% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 13.21% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 47.29% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 50.40% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 28.17% |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | 18.05% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.05% |
| Mar 31, 2026 | 13.52% |
| Dec 31, 2025 | 5.85% |
| Sep 30, 2025 | 6.11% |
| Jun 30, 2025 | 14.82% |
| Mar 31, 2025 | 18.07% |
| Dec 31, 2024 | 6.90% |
| Sep 30, 2024 | 0.63% |
| Jun 30, 2024 | 23.11% |
| Mar 31, 2024 | 7.13% |
| Dec 31, 2023 | 18.48% |
| Sep 30, 2023 | 12.71% |
| Jun 30, 2023 | -10.34% |
| Mar 31, 2023 | 5.01% |
| Dec 31, 2022 | 2.72% |
| Sep 30, 2022 | -10.63% |
| Jun 30, 2022 | -4.78% |
| Mar 31, 2022 | -5.30% |
| Dec 31, 2021 | 2.57% |
| Sep 30, 2021 | -9.76% |